13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001631134
Total reported value
$1.9B
$1.9B
69 檔
44.3%
As reported in its official Q1 2026 Form 13F filing, Sofinnova Investments, Inc.'s tracked investment portfolio stood at $1.9B with 69 total positions.
In Q1 2026, Sofinnova Investments, Inc. displayed an active expansion posture, initiating 25 new positions and adding to 24 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 11.78% | +9.98% | — | |
| 2 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 5.66% | -5.66% | EXIT | |
| 3 | UTHR | United Therapeutics CORP | Stock-Healthcare | 5.42% | -3.28% | +52.48% | |
| 4 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 5.10% | -5.10% | EXIT | |
| 5 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 4.58% | -1.97% | +31.44% | |
| 6 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 4.30% | +0.25% | -37.67% | |
| 7 | VERA | Vera Therapeutics Inc | Stock-Other | 4.27% | +1.93% | — | |
| 8 | AZN | AstraZeneca PLC | Stock-Healthcare | 3.42% | -3.42% | EXIT | |
| 9 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 3.29% | -3.29% | EXIT | |
| 10 | COGT | Cogent Biosciences Inc | Stock-Other | 3.09% | -1.02% | +7.09% | |
| 11 | IBB | Ishares Biotechnology ETF | ETF-Tech | 3.05% | -3.05% | EXIT | |
| 12 | CELC | Celcuity Inc | Stock-Other | 2.89% | -2.89% | EXIT | |
| 13 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.78% | +1.05% | +4096.74% | |
| 14 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.65% | -0.62% | +3264.97% | |
| 15 | RAPP | Rapport Therapeutics Inc | Stock-Other | 2.26% | +1.84% | — | |
| 16 | INSM | Insmed Inc | Stock-Healthcare | 2.15% | -1.28% | +120.71% | |
| 17 | ALC | Alcon Inc. | Stock-Healthcare | 2.09% | -1.20% | +119.53% | |
| 18 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 1.87% | +0.62% | +72.54% | |
| 19 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.68% | -0.62% | +12.17% | |
| 20 | BIIB | Biogen Inc | Stock-Healthcare | 1.60% | -1.60% | EXIT | |
| 21 | BIOA | Bioage Labs Inc | Stock-Other | 1.52% | +1.39% | — | |
| 22 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.49% | +0.85% | +65.85% | |
| 23 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.49% | +1.56% | — | |
| 24 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.43% | +0.35% | +27.87% | |
| 25 | IMNM | Immunome Inc | Stock-Other | 1.41% | +0.47% | +5.15% | |
| 26 | NKTR | Nektar Therapeutics | Stock-Other | 1.39% | +0.31% | +16.17% | |
| 27 | ✓ | Immatics NV | Stock-Other | 1.36% | +0.56% | +5.67% | |
| 28 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.15% | -1.15% | EXIT | |
| 29 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.13% | +0.77% | -27.52% | |
| 30 | INBX | Inhibrx Biosciences Inc | Stock-Other | 1.04% | +0.44% | -10.70% | |
| 31 | DXCM | Dexcom Inc | Stock-Healthcare | 0.94% | -0.94% | EXIT | |
| 32 | PHVS | Pharvaris N.V. | Stock-Other | 0.88% | +0.70% | +9.82% | |
| 33 | PFE | Pfizer Inc | Stock-Healthcare | 0.85% | -0.85% | EXIT | |
| 34 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.78% | -0.67% | -49.35% | |
| 35 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.77% | +4.97% | — | |
| 36 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.76% | +0.75% | -15.83% | |
| 37 | LQDA | Liquidia CORP | Stock-Other | 0.72% | -0.72% | EXIT | |
| 38 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.67% | -0.67% | EXIT | |
| 39 | SYK | Stryker CORP | Stock-Healthcare | 0.56% | -0.56% | EXIT | |
| 40 | ANAB | Anaptysbio Inc | Stock-Other | 0.52% | +1.20% | -13.71% | |
| 41 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.51% | -0.51% | EXIT | |
| 42 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.50% | -0.50% | EXIT | |
| 43 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.46% | +0.34% | -11.72% | |
| 44 | EXEL | Exelixis Inc | Stock-Healthcare | 0.41% | +0.31% | — | |
| 45 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.33% | -0.33% | EXIT | |
| 46 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.31% | -0.31% | EXIT | |
| 47 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.30% | -0.25% | — | |
| 48 | REPL | Replimune Group Inc | Stock-Other | 0.30% | -0.30% | EXIT | |
| 49 | AXGN | Axogen Inc | Stock-Other | 0.27% | -0.27% | EXIT | |
| 50 | DFTX | Definium Therapeutics Inc | Stock-Other | 0.25% | +0.37% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RARE | Ultragenyx Pharmaceutical In | +2.7% | +4096.74% | Add |
| 2 | AXSM | Axsome Therapeutics Inc | +2.6% | +3264.97% | Add |
| 3 | UTHR | United Therapeutics CORP | +2.1% | +52.48% | Add |
| 4 | CELC | Celcuity Inc | +1.6% | +122.49% | Add |
| 5 | BMY | Bristol-myers Squibb Co | +1.1% | +31.44% | Add |
| 6 | INSM | Insmed Inc | +1% | +120.71% | Add |
| 7 | ALC | Alcon Inc. | +1% | +119.53% | Add |
| 8 | SUPN | Supernus Pharmaceuticals Inc | +0.7% | +72.54% | Add |
| 9 | NKTR | Nektar Therapeutics | +0.6% | +16.17% | Add |
| 10 | XENE | Xenon Pharmaceuticals Inc | +0.6% | +409.54% | Add |
| 11 | RYTM | Rhythm Pharmaceuticals Inc | +0.2% | +65.85% | Add |
| 12 | BIOA | Bioage Labs Inc | +0.2% | — | Unchanged |
| 13 | IDYA | Ideaya Biosciences Inc | +0.1% | +27.87% | Add |
| 14 | COGT | Cogent Biosciences Inc | +0.1% | +7.09% | Add |
| 15 | AVBP | Arrivent Biopharma Inc | 0% | — | Unchanged |
| 16 | MIRM | Mirum Pharmaceuticals Inc | 0% | +19.44% | Add |
| 17 | SVRA | Savara Inc | — | +19.68% | Add |
| 18 | SLNOEUR | Soleno Therapeutics Inc | — | +18.33% | Add |
| 19 | IMA | Imagenebio Inc | — | — | Unchanged |
| 20 | PHVS | Pharvaris N.V. | 0% | +9.82% | Add |
| 21 | EWTX | Edgewise Therapeutics Inc | 0% | -11.72% | Trim |
| 22 | BOLT | Bolt Biotherapeutics Inc | 0% | — | Unchanged |
| 23 | JBIO | Jade Biosciences Inc | 0% | — | Unchanged |
| 24 | ACAD | Acadia Pharmaceuticals Inc | 0% | +19.80% | Add |
| 25 | ✓ | Establishment Labs Holdings In | 0% | +19.61% | Add |
| 26 | NXTC | Nextcure Inc | -0.1% | — | Unchanged |
| 27 | WVE | Wave Life Sciences Ltd. | -0.1% | +19.64% | Add |
| 28 | ANAB | Anaptysbio Inc | -0.1% | -13.71% | Trim |
| 29 | IMNM | Immunome Inc | -0.1% | +5.15% | Add |
| 30 | BMRN | Biomarin Pharmaceutical Inc | -0.1% | +12.17% | Add |
| 31 | DXCM | Dexcom Inc | -0.1% | +4.06% | Add |
| 32 | IRON | Disc Medicine Inc | -0.2% | -29.45% | Trim |
| 33 | ROIV | Roivant Sciences Ltd. | -0.2% | -34.93% | Trim |
| 34 | ✓ | Immatics NV | -0.2% | +5.67% | Add |
| 35 | RAPP | Rapport Therapeutics Inc | -0.2% | — | Unchanged |
| 36 | CMPX | Compass Therapeutics Inc | -0.3% | -24.05% | Trim |
| 37 | RCUS | Arcus Biosciences Inc | -0.4% | -15.83% | Trim |
| 38 | INBX | Inhibrx Biosciences Inc | -0.5% | -10.70% | Trim |
| 39 | DYN | Dyne Therapeutics Inc | -0.8% | -27.52% | Trim |
| 40 | PRAX | Praxis Precision Medicines I | -0.8% | -49.35% | Trim |
| 41 | BBIO | Bridgebio Pharma Inc | -1.2% | -43.20% | Trim |
| 42 | VERA | Vera Therapeutics Inc | -1.8% | — | Unchanged |
| 43 | JAZZ | Jazz Pharmaceuticals plc | -2.7% | -37.67% | Trim |
| 44 | NTRA | Natera Inc | -3.5% | — | Unchanged |
| 45 | AZNN | Astrazeneca Plc-spons Adr | — | EXIT | Sold out |
| 46 | IWM | Ishares Russell 2000 ETF | — | NEW | New buy |
| 47 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 48 | AZN | AstraZeneca PLC | — | NEW | New buy |
| 49 | QQQ | Invesco Qqq Trust Series 1 | — | NEW | New buy |
| 50 | IBB | Ishares Biotechnology ETF | — | NEW | New buy |
According to official SEC Form 13F filings, Sofinnova Investments, Inc. reported a total U.S. public equity portfolio value of $1.9B across 69 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, IWM, UTHR) accounted for 44.3% of total reported equity market value during Q1 2026.
Top New Position Initiated
IWM
市值: $148.8M
Top Position Liquidated / Trimmed
AZNN
前期市值: $150.1M
During Q1 2026, Sofinnova Investments, Inc.'s top holdings by market value included NTRA (11.8%)、IWM (5.7%)、UTHR (5.4%). The largest single position, NTRA, represented 11.8% of total portfolio value.
In Q1 2026, Sofinnova Investments, Inc. made 76 total portfolio adjustments, initiating 25 new buys, adding to 24 positions, trimming 11 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.